CoChat

CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma

Open access
Liu, S. John, Malatesta, Martina, Lien, Brian V., Saha, Parna, Thombare, Shivani S., Hong, Sung Jun, Pedraza, Leslie, Koontz, Mark, Seo, Kyounghee, Horlbeck, Max A., He, Daniel, Birk, Harjus S., Jain, Miten, Olsen, Hugh E., Akeson, Mark, Weissman, Jonathan S., Monje, Michelle, Gupta, Nalin, Raleigh, David R., Ullian, Erik M., Lim, Daniel A. · 2020 · Genome Biology
Cited by 138

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background: Long non-coding RNAs (lncRNAs) exhibit highly cell type-specific expression and function, making this class of transcript attractive for targeted cancer therapy. However, the vast majority of lncRNAs have not been tested as potential therapeutic targets, particularly in the context of currently used cancer treatments. Malignant glioma is rapidly fatal, and ionizing radiation is part of the current standard-of-care used to slow tumor growth in both adult and pediatric patients. Results: We use CRISPR interference (CRISPRi) to screen 5689 lncRNA loci in human glioblastoma (GBM) cells, identifying 467 hits that modify cell growth in the presence of clinically relevant doses of fractionated radiation. Thirty-three of these lncRNA hits sensitize cells to radiation, and based on their expression in adult and pediatric gliomas, nine of these hits are prioritized as lncRNA Glioma Radiation Sensitizers (lncGRS). Knockdown of lncGRS-1, a primate-conserved, nuclear-enriched lncRNA, inhibits the growth and proliferation of primary adult and pediatric glioma cells, but not the viability of normal brain cells. Using human brain organoids comprised of mature neural cell types as a three-dimensional tissue substrate to model the invasive growth of glioma, we find that antisense oligonucleotides targeting lncGRS-1 selectively decrease tumor growth and sensitize glioma cells to radiation therapy. Conclusions: These studies identify lncGRS-1 as a glioma-specific therapeutic target and establish a generalizable approach to rapidly identify novel therapeutic targets in the vast non-coding genome to enhance radiation therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13059-020-01995-4

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 138

Metadata

Authors
Liu, S. J., Malatesta, M., Lien, B. V., Saha, P., Thombare, S. S., Hong, S. J., Pedraza, L., Koontz, M., Seo, K., Horlbeck, M. A., He, D., Birk, H. S., Jain, M., Olsen, H. E., Akeson, M., Weissman, J. S., Monje, M., Gupta, N., Raleigh, D. R., Ullian, E. M., & Lim, D. A.
Venue
Genome Biology
Published
2020-03-31
Volume
21
Issue
1
Pages
83-83
ISSN
  • 1465-6906 (ISSN-L)
  • 1474-760X
OpenAlex
W3014756290
Cited by
138
References
29
FWCI
5.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. https://app.cochat.ai/papers/10.1186/s13059-020-01995-4
The paper
Liu, S. J., Malatesta, M., Lien, B. V., Saha, P., Thombare, S. S., Hong, S. J., Pedraza, L., Koontz, M., Seo, K., Horlbeck, M. A., He, D., Birk, H. S., Jain, M., Olsen, H. E., Akeson, M., Weissman, J. S., Monje, M., Gupta, N., Raleigh, D. R., . . . Lim, D. A. (2020). CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biology. https://doi.org/10.1186/s13059-020-01995-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.